Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1621536 | 0.98 | ALDH1A1 (0.37) | ALDH1A1FKBP1AMAPTCYP4F2CYP4A11 | |
| SCHEMBL766823 | 0.85 | CNR1 (0.32) | MAPTCYP4F2CYP4A11KMT2AMEN1 | |
| SCHEMBL766710 | 0.85 | CNR2 (0.41) | ALDH1A1MAPTCYP4F2CYP4A11KMT2A | |
| SCHEMBL10171728 | 0.85 | CNR1 (0.32) | MAPTCYP4F2CYP4A11KMT2AMEN1 | |
| SCHEMBL2184475 | 0.85 | CNR1 (0.32) | MAPTCYP4F2CYP4A11KMT2AMEN1 | |
| SCHEMBL1691527 | 0.82 | HTT (0.50) | ALDH1A1MAPTATML3MBTL1KMT2A | |
| SCHEMBL10171700 | 0.76 | ALDH1A1 (0.36) | ALDH1A1FKBP1AMAPTTHRBATM | |
| SCHEMBL3782901 | 0.76 | LMNA (0.44) | ALDH1A1MAPTTHRBATML3MBTL1 | |
| SCHEMBL3783558 | 0.74 | LMNA (0.46) | ALDH1A1MAPTTHRBATML3MBTL1 | |
| SCHEMBL1621233 | 0.74 | CNR2 (0.31) | ALDH1A1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315454-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-9315454-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-9315454-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-8829034-B2 | Compounds which modulate the CB2 receptor | Boehringer Ingerlheim International GmbH (DE) | 2014-09-09 | — | — | US | disclosed |
| US-8829034-B2 | Compounds which modulate the CB2 receptor | Boehringer Ingerlheim International GmbH (DE) | 2014-09-09 | — | — | US | disclosed |
| US-8829034-B2 | Compounds which modulate the CB2 receptor | Boehringer Ingerlheim International GmbH (DE) | 2014-09-09 | — | — | US | disclosed |
| EP-2342199-B1 | Sulfonyl compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INT (DE) | 2014-02-26 | — | — | EP | disclosed |
| EP-2074084-B1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2013-08-28 | — | — | EP | disclosed |
| EP-2074084-B1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2013-08-28 | — | — | EP | disclosed |
| US-8383651-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-25 | — | — | US | disclosed |
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | US | disclosed |
| WO-2008039645-A1 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081822-A1 | N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain | CNR2, CNR1, OPRL1 | ALDH1A1 2404/4885FKBP1A 1090/4885MAPT 2865/4885 |
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 2112/4885FKBP1A 704/4885MAPT 3858/4885 |
| US-20100076029-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 2112/4885FKBP1A 704/4885MAPT 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.